Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the U.S. Food and Drug Administration (FDA) has accepted for priority ...

Monoamine oxidase inhibitors were linked to the highest risk for cardiovascular Standardized MedDRA Queries. Dopamine reuptake inhibition and binding inhibition are linked to antidepressant-related ...

Centanafadine is a serotonin-norepinephrine-dopamine reuptake inhibitor. The two, 6-week, multicenter, double-blind, placebo-controlled trials (Study 1 and Study 2) evaluated the efficacy and safety ...

The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...

FDA fast tracks ADHD drug centanafadine, targeting approval by July 24 for treatment across all age groups, based on phase 3 trial results.

This story was reviewed by Daniel Z. Lieberman, MD. Maybe you’re neck-deep in a two-week funk you just can’t seem to shake, or perhaps you’ve been struggling with severe depression for years. No ...

NEW YORK, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today an exclusive ...

Enveric Biosciences (NASDAQ:ENVB) announced the discovery of multiple compounds sourced using its Psybrary platform and proprietary computational chemistry and artificial intelligence (AI) ...

Recent use of selective serotonin reuptake inhibitors (SSRIs) may reduce the treatment response to 3,4-methylenedioxymethamphetamine (MDMA)–assisted psychotherapy for posttraumatic stress disorder ...